Sanofi licenses Sino Biopharm’s JAK/ROCK drug for $1.4B
Sanofi licenses Sino Biopharm’s JAK/ROCK drug for $1.4B
Body unavailable. Use the original source.
Sanofi licenses Sino Biopharm’s JAK/ROCK drug for $1.4B
A compact weekly email covering company moves, product signals, regulatory updates, and notable funding.